FAQ: What Qualifies as an Adaptogen?

“Adaptogen" has become one of the most heavily used descriptors in the supplement industry, applied to everything from ashwagandha capsules to mushroom coffee to stress-support gummies.

But the term has no formal regulatory definition in the United States, and it could be argued that the scientific criteria behind it are narrower, and older, than most marketing language suggests.

For formulators building claims around adaptogenic ingredients, understanding where the term actually comes from, and where the evidence and regulatory risk sit, matters as much as the ingredient science itself.

What Is the Formal Definition of an Adaptogen?

The most widely cited scientific definition comes from a 2021 pharmacology review, which states that "adaptogens must be innocuous and cause minimal disorder in the physiological functions of an organism, and have nonspecific actions," and elsewhere describes their effect as a "normalizing action irrespective of the direction of the foregoing pathologic changes."¹

In practice, that means a true adaptogen is expected to meet 3 conditions: low toxicity at normal doses, an effect that isn't limited to 1 specific type of stress, and an action that pushes the body's stress response back toward balance rather than pushing it in a fixed direction.

Who Coined the Term, and How Has the Definition Evolved?

The term originated with Russian toxicologist Nikolay Lazarev, who introduced "adaptogen" in 1958 to describe synthetic and plant-derived compounds capable of increasing the body's nonspecific resistance to stress.¹

The concept grew out of Soviet World War II-era research into Schisandra chinensis and related botanicals as alternatives to synthetic stimulants for military and industrial performance.¹ Later, Soviet researchers, including Israel Brekhman, refined the concept into a more formal set of pharmacological criteria, and it has since been revisited and expanded by subsequent research groups as the underlying mechanisms, largely involving the body's stress-response signaling systems, have become better understood.

Despite that refinement, the term developed almost entirely within Soviet, and later broader Eastern European and Asian, pharmacological research traditions rather than within Western regulatory science, which is part of why its status in the US and EU remains unsettled today.

Which Ingredients Are Typically Classified as Adaptogens?

There is no official list, but a relatively consistent core group appears across pharmacological literature and industry usage: Withania somnifera (ashwagandha), Rhodiola rosea, Panax ginseng and related Panax species, Eleutherococcus senticosus (eleuthero, formerly Siberian ginseng), Schisandra chinensis, and Andrographis paniculata.

Beyond that core group, the term is applied far more loosely in the marketplace to ingredients including holy basil, cordyceps, reishi, and other adaptogen-adjacent mushrooms and botanicals, several of which have considerably less clinical research behind an adaptogenic mechanism specifically, as distinct from other proposed health benefits.

What Does the Clinical Evidence Actually Show?

Evidence quality varies significantly by ingredient. A 2023 systematic review and meta-analysis of 25 studies across nine adaptogenic herbs found that Withania somnifera showed meaningful reductions in both serum cortisol and perceived stress scores compared with placebo after 8 to 9 weeks of use, one of the more consistently replicated findings in the category.²

Other ingredients in the review had thinner or more mixed evidence, and the authors' scope was limited to plant-based adaptogens with available randomized data, meaning ingredients marketed as adaptogens without comparable human trials, such as many adaptogenic mushroom products, fell outside what the review could evaluate at all. The overall picture is an evidence base that supports a nonspecific stress-modulating effect for a handful of well-studied botanicals, rather than for the category as a whole.

Is "Adaptogen" a Legally Defined or Regulated Term?

No, not in the United States. The FDA does not recognize "adaptogen" as a formal regulatory category, and the agency has issued warning letters to dietary supplement companies over marketing claims tied to the term when those claims crossed into implying the product could treat, cure, or prevent a disease, which would classify it as an unapproved new drug rather than a lawfully marketed supplement.³

The European Medicines Agency has gone further than the FDA procedurally: its Committee on Herbal Medicinal Products published a reflection paper in 2008 specifically attempting to define "adaptogen" and set assessment criteria for herbal products making adaptogenic claims, though that effort was a scientific discussion document rather than a formal, binding regulatory definition adopted into EU herbal medicine law.⁴

That regulatory vacuum cuts both ways for formulators: it means "adaptogen" itself isn't a claim requiring specific substantiation the way a structure/function claim would be, but any specific benefit implied alongside it, stress relief, cortisol reduction, energy support, still needs to meet the same substantiation standard as any other supplement claim.

What Should Formulators Keep in Mind When Making Adaptogen Claims?

Using "adaptogen" as a descriptive term is generally lower-risk than the specific claims often paired with it. The larger exposure comes from vague or disease-adjacent language, framing a product as treating anxiety, chronic fatigue, or hormonal imbalance, rather than supporting the body's general stress response, since that shift moves a claim from structure/function territory into implied drug-claim territory.

Formulators should also be able to distinguish, internally and in technical documentation, between ingredients with genuine randomized clinical support for a stress-modulating effect and those included in a formula primarily because "adaptogen" has become a popular category descriptor rather than because of ingredient-specific evidence.

References

1. Panossian AG, Efferth T, Shikov AN, et al. Evolution of the adaptogenic concept from traditional use to medical systems: pharmacology of stress- and aging-related diseases. Med Res Rev. 2021;41(1):630-703. doi:10.1002/med.21743

2. Tóth-Mészáros A, Garmaa G, Hegyi P, et al. The effect of adaptogenic plants on stress: a systematic review and meta-analysis. J Funct Foods. 2023;108:105695. doi:10.1016/j.jff.2023.105695

3. Warning Letters - Health Fraud. US Food and Drug Administration. December 4, 2025. Accessed August 31, 2026. https://www.fda.gov/consumers/health-fraud-scams/warning-letters-health-fraud

4. Adaptogenic concept – Scientific guideline. European Medicines Agency. Published 2008. Accessed August 31, 2026. https://www.ema.europa.eu/en/adaptogenic-concept